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MMP9 modulates the metastatic cascade and immune
landscape for breast cancer anti-metastatic therapy
Mark Owyong1,*, Jonathan Chou1,2,5,* , Renske JE van den Bijgaart1, Niwen Kong1, Gizem Efe1, Carrie Maynard1,
Dalit Talmi-Frank6, Inna Solomonov6 , Charlotte Koopman1, Elin Hadler-Olsen1 , Mark Headley3, Charlene Lin1,
Chih-Yang Wang1, Irit Sagi6, Zena Werb1,5, Vicki Plaks1,4
Metastasis, themain cause of cancer-related death, has traditionally
been viewed as a late-occurring process during cancer progression.
Using the MMTV-PyMT luminal B breast cancer model, we demon-
strate that the lung metastatic niche is established early during
tumorigenesis. We found that matrix metalloproteinase 9 (MMP9) is
an important component of the metastatic niche early in tumori-
genesis and promotes circulating tumor cells to colonize the lungs.
Blocking active MMP9, using a monoclonal antibody specific to the
active form of gelatinases, inhibited endogenous and experimental
lungmetastases in theMMTV-PyMTmodel. Mechanistically, inhibiting
MMP9 attenuated migration, invasion, and colony formation and
promotedCD8+ T cell infiltration andactivation. Interestingly, primary
tumor burdenwas unaffected, suggesting that inhibiting activeMMP9
is primarily effective during the early metastatic cascade. These
findings suggest that the early metastatic circuit can be disrupted by
inhibiting activeMMP9 andwarrant further studies ofMMP9-targeted
anti-metastatic breast cancer therapy.
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Introduction
Most cancer-related deaths are due to metastatic disease. Metas-
tasis, one of the classic “hallmarks of cancer” (Hanahan & Weinberg,
2011), is a multistage process that includes remodeling the local
tumor microenvironment (TME), followed by invasion of tumor cells
into the blood or lymph, survival in circulation, extravasation, and
growth in a new microenvironment. The recognition that cancer is a
systemic disease has been illustrated by studies showing the im-
portance of various cell types in creating ametastatic niche (Lambert
et al, 2017), and the role of the immune system in tumor growth
(Aguado et al, 2017). However, although numerous studies have
delineated mechanisms during the late stages of metastasis, there is
little understanding about how early these niches are initiated
during tumorigenesis and how they can be disrupted from a ther-
apeutic standpoint. Importantly, there are currently no approved
therapies that specifically aim to inhibit new sites of tumor growth.
The ECM, a critical component of the TME, undergoes extensive
remodeling during breast cancer (BC) evolution. Matrix metal-
loproteinases (MMPs), a family of zinc-dependent endopeptidases,
are pivotal players in ECM remodeling during cancer initiation and
progression via multiple mechanisms (Kessenbrock et al, 2010;
Bonnans et al, 2014). For example, in the primary tumor, MMPs
cleave, degrade, and rearrange the components of the ECM. In
addition, MMPs activate cytokines and release sequestered growth
factors, thereby regulating many different pathological processes
(Noel et al, 2012). Notably, active (rather than total) levels of cir-
culating proteases, including MMP2 andMMP9, play a role in human
BC classification and progression (Somiari et al, 2006). MMP9 ex-
pression correlates with more aggressive subtypes of BC and is
associated with a higher incidence of metastasis and relapse
(Vizoso et al, 2007; Waldron et al, 2012; Yousef et al, 2014). Fur-
thermore, MMP9 is instrumental in establishing the metastatic
niche (Hiratsuka et al, 2002; Kaplan et al, 2005) and functions as a
key mediator in metastatic progression.
In the metastatic niche, myeloid cells have been implicated in locally
supplying the niche with abundant quantities of MMPs (Yan et al, 2010).
We and others have shown that CD11b+Gr1+ myeloid cells accumulate in
the metastatic lungs of mammary tumor virus (MMTV) promoter-driven
polyomamiddle T antigen (PyMT)mice (Kowanetz et al, 2010; Casbonet al,
2015; Wculek & Malanchi, 2015) and are involved in mediating metastatic
niche formation. These myeloid cells decrease IFNγ production and
elevate T helper 2 (Th2) cytokines, while producing large quantities of
MMP9 that later promote vascular remodeling (Yan et al, 2010). This
suggests that these cells alter the overall landscape of the metastatic
lung microenvironment and tip the balance of immune protection to
tumor promotion. Although immune subsets play the predominant role
in supplying MMPs, tumor cells also contribute a variety of MMPs that aid
in priming the metastatic niche (Köhrmann et al, 2009).
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Not surprisingly, given the pleiotropic roles of MMPs in cancer
transformation and metastasis, there has been considerable
clinical interest in MMP inhibitors. However, most clinical trials
using small molecule MMP inhibitors were unsuccessful because of
poor tolerability and lack of efficacy stemming from low specificity
(Coussens et al, 2002). In addition, MMP inhibitors were given as
monotherapy in patients with advanced metastatic disease and,
thus, the therapeutic potential of targeting MMPs at earlier stages of
disease was not evaluated (Deryugina & Quigley, 2006). By mim-
icking how endogenous tissue inhibitors of metalloproteinases
bind to MMPs, we generated a specific blocking monoclonal anti-
body (referred to as SDS3) directed against the catalytic zinc–
protein complex and enzyme surface (exosites) of the activated
forms of MMP2 and MMP9 (Sela-Passwell et al, 2011).
Because metastatic dissemination is initiated early during tu-
morigenesis, we used the MMTV-PyMT immune competent mouse
model. This model recapitulates the natural progression of human
luminal B BC, which is hormone receptor–positive (estrogen re-
ceptor and/or progesterone receptor–positive) and either HER2
positive or negative and exhibits a less favorable prognosis com-
pared with luminal A BC (Inic et al, 2014). In MMTV-PyMT mice, the
expression of biomarkers in tumors is similar to those associated
with poor outcomes in humans, including the loss of estrogen
receptor and progesterone receptor and the persistent expression
of ErbB2/Neu and cyclin D1 (Lin et al, 2003). In this study, we show
that in MMTV-PyMT mice, a metastatic niche is established early
during tumorigenesis and promotes lung colonization by circu-
lating tumor cells (CTCs). Using complementary genetic and
pharmacological approaches, we demonstrate that MMP9 plays a
critical role in these early steps of metastasis. Blocking active MMP9
early during tumorigenesis inhibits metastatic colonization and
opens a strategy to effectively target metastatic disease.
Results
A lung metastatic niche is established early during BC
transformation
To investigate the lung metastatic niche in early BC, we compared the
ability of i.v.–injected tumor cells to grow in the lungs of female MMTV-
PyMT mice and their wild-type (WT) littermates. We used an MMTV-
PyMT–derived cell line generated by Lynch and colleagues (Halpern et
al, 2006) that we labeled with GFP and luciferase (referred to here as
probing VO-PyMT cells) to mimic CTCs and probe their ability to col-
onize the lungs. Reporter genes in VO-PyMT cells distinguished them
from any endogenous, spontaneous metastases. To understand the
changes early during tumorigenesis, we i.v. injected the probing VO-
PyMT cells into 6-wk-oldMMTV-PyMT andWT littermates (Fig 1A). At this
stage, MMTV-PyMT mice begin to form hyperplasias and early ade-
nomas, and, importantly, there were no spontaneous micrometastatic
foci present in the lungs (Fig S1A). We then monitored the mice
longitudinally using bioluminescent imaging. 4 wk after i.v. injection,
MMTV-PyMT mice showed a significantly increased lung metastatic
burden from the injected probing cells compared with their WT lit-
termates (Figs 1B and S1B). Interestingly, 2 wk after i.v. injection, when
the bioluminescent signal was still undetectable, MMTV-PyMT mice
already exhibited a higher micrometastatic burden than WT mice by
microscopic examination of the GFP signal (Figs 1C and S1C). Although
PyMT is not expressed on the cell surface, cross-presentation of en-
dogenous antigens could hypothetically lead to immune tolerance in
MMTV-PyMT and not WT mice. To mitigate the concern that VO-PyMT
cells colonize the lungs better inMMTV-PyMTmice because of immune
tolerance to the PyMT antigen expressed in the primary tumor (Lin et al,
2003), we injected an independent, non-PyMT lung adenocarcinoma
cell line (LAP0297, derived from FVB background [Huang et al, 2008])
into MMTV-PyMT and WT littermates (Fig 1D and E) and also observed
increased lung metastatic burden in MMTV-PyMT mice. These data
demonstrate that the lung microenvironment in MMTV-PyMT mice is
more permissive to the growth of i.v.–injected probing cells, even
during the pre-metastatic stages of tumorigenesis.
To further support our observations that systemic alterations
occur early during tumorigenesis, we used a non-metastatic MMTV-
PyMT model (DB-MMTV-PyMT), which carries a mutation in PyMT
that decouples it from phosphatidylinositol 3-kinase (PI3K) sig-
naling. These mice form hyperplasias and adenomas in all mam-
mary glands, but rarely progress to carcinoma or develop lung
metastases (Hutchinson et al, 2001). We found that DB-MMTV-PyMT
mice i.v. injected with VO-PyMT cells were also more permissive for
metastatic growth when compared withWT littermates (Fig S1D and E).
This further suggests that early events during tumor progression
promote metastatic colonization and that factors from the hyper-
plastic primary tumor prime the lung microenvironment.
Systemic inhibition of active MMP9 abrogates metastatic growth
in the lungs of MMTV-PyMT mice but does not attenuate primary
tumor growth
To understand the changes that occur in these early hyperplasias,
we profiled gene expression and found that at 6 wk of age, MMTV-
PyMT hyperplasias expressed increased levels of multiple ECM
components, remodeling enzymes (including MMPs), angiogenic
and inflammatory factors, and Th2 cytokines implicated in medi-
ating metastatic niche formation (Fig S1F) (Hiratsuka et al, 2002; Yan
et al, 2010; Casbon et al, 2015).
Moreover, previous work demonstrated that inflammatory my-
eloid cells are a major source of MMP9 in primary tumors, and that
these cells are critical in establishing the lung metastatic niche
(Kowanetz et al, 2010; Yan et al, 2010). We sought to characterize this
population of neutrophils and monocytes, which expresses the
surface markers CD11b and Gr1. Although cells expressing these
markers are frequently called myeloid-derived suppressor cells
(Markowitz et al, 2013), in the MMTV-PyMT model most cells closely
resemble neutrophils (Casbon et al, 2015). These CD11b+Gr1+ cells
participate in ECM degradation, angiogenesis, and suppression of
CD4+ and CD8+ T cell proliferation (Yan et al, 2010; Casbon et al,
2015). 6-wk-old MMTV-PyMT mice i.v. injected with VO-PyMT cells
accumulated CD11b+Gr1+ cells as well as CD11b+ DCs, macrophages,
and conventional monocytes (migratory DCs that activate T cells) in
the lungs after a 3-wk chase, as compared with WT littermates (Figs
2A and S2A). The CD11b+Gr1+ cells formed clusters surrounding
metastatic islands of GFP+ VO-PyMT cells, whereas Gr1+ cells were
sparse but evenly distributed within GFP− areas of the lungs (Fig 2B).
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Figure 1. Characterization of a pre-metastatic niche in the lungs of MMTV-PyMT mice.
The lung microenvironment of hyperplastic MMTV-PyMTmice is permissive to the growth of i.v. injected circulating VO-PyMT tumor cells. (A) Schematic of the experimental
setup: 6-wk-old MMTV-PyMT mice or WT littermate controls were i.v. injected with 1 × 105 VO-PyMT-GFP-Luc cells. The mice were monitored weekly using bioluminescence
imaging and euthanized 2 and 4 wk after i.v. injection. The lungs were evaluated by whole-mount fluorescence imaging to detect and quantify lung metastases. (B) Left:
bioluminescence imaging ofWT littermate control (top) andMMTV-PyMT (bottom)mice 4 wk after i.v. injection of VO-PyMT-Luc-GFP probing cells (n = 10WT and n = 10 PyMT).
Middle: left—representative hematoxylin and eosin (H&E)–stained images of lung metastases in WT littermate control and MMTV-PyMT mice. Scale bar is 200 μm;
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We next examined MMP2 and MMP9, which are expressed in
primary MMTV-PyMT tumors (Fig S2B), across BC subtypes of
human primary tumors and metastases (including nine matched
pairs) to the chest wall, lymph nodes, lungs, liver, and spleen
(Waldron et al, 2012). Among all 24 MMPs examined using publicly
available microarray data (Waldron et al, 2012), MMP9, which is
known to be pro-tumorigenic, was the only one significantly
elevated in metastasis (Figs 2C and S2C). After i.v. injection of
VO-PyMT cells, MMP9 co-localized with Gr1+ cells but was also
detected in Gr1− cells in the lungs of MMTV-PyMTmice (Fig 2D). This
suggests that these myeloid cells are a predominant cell type that
secretes MMP9 into the MMTV-PyMT metastatic niche, although
other cells, including myeloid, stromal, and/or tumor cells, may
also be a source of MMP9 (Psaila & Lyden, 2009) and contribute to
metastatic colonization. We then examined the functional rele-
vance of MMP9 by using MMP9 KO mice (Vu et al, 1998) to assess
the effect of genetic ablation of MMP9 in the MMTV-PyMT model.
Using MMTV-PyMT; MMP9 KO mice i.v.-injected with VO-PyMT cells,
we found that MMP9 KO mice have reduced lung metastasis with
no change in primary tumor burden (Fig 2E and F). This provided a
proof-of-concept for the potential importance of MMP9 in met-
astatic growth and underlied MMP9 as a potential therapeutic
target within the TME.
Using in situ zymography, we found that the lungs of MMTV-PyMT
mice had significantly higher levels of gelatinase activity at ade-
noma and carcinoma stages of tumorigenesis, starting at 8 wk of
age as compared with WT controls (Figs 2G and S2D). Interestingly,
the increase in gelatinase activity coincided with the time point at
which we detected a significant difference in the ability of VO-PyMT
cells to colonize the lungs in the MMTV-PyMT model (Fig 1C). Col-
lectively, these data suggest that increased MMP9 expression and
activity in the lungs may be an important mediator in initiating and
maintaining the metastatic niche.
Since active MMP9 is more relevant to disease than total MMP9
(Somiari et al, 2006), we next determined whether blocking active
MMP9 would alter the ability of VO-PyMT cells to colonize the
lungs of MMTV-PyMT mice. We treated MMTV-PyMT mice with SDS3
or control immunoglobulin (IgG), starting before and continuing
every 2 d after i.v. injection of the VO-PyMT cells (Fig 2H). Although
both MMP2 and MMP9 were present in primary tumors (Fig S2B),
SDS3 reduced the metastatic growth of VO-PyMT probing cells in
the lungs of MMTV-PyMT mice (Fig 2I) without affecting primary
tumor growth (Fig 2J). We verified that SDS3 treatment reduced
gelatinase activity in the lungs using in situ zymography (Figs 2K
and S2E). These results demonstrated that metastatic coloniza-
tion is facilitated by active MMP9 and that blockade of its activity
primarily suppressed metastatic tumor growth in the lungs,
without affecting primary tumor burden.
SDS3 is biodistributed to tumor and metastatic foci and
specifically associated with myeloid cells
Because SDS3 treatment in vivo attenuates metastatic colonization
in MMTV-PyMT mice, we examined the biodistribution of SDS3. We
crossbred MMTV-PyMT mice with the ACTB-ECFP (β-actin promoter
driving enhanced cyan fluorescent protein) and c-fms (colony
stimulating factor 1 receptor)-EGFP reporter mice to enable visu-
alization of different tumor stages andmyeloid cell dynamics. Using
fluorescently-labeled SDS3 (SDS3-HyLite 555, i.p. injected 3 or 24 h
before imaging) in the transgenic reporter models, we observed
SDS3-HyLite 555-positive cells within the stroma surrounding the
primary tumor foci (Figs 3A and S3A, Videos 1, 2, and 7). Some cells
that took up SDS3-HyLite 555 also took up dextran, suggesting that
these are macrophages expressing CD68 and CD206 (Egeblad et al,
2008), with some nonspecific uptake because of opsonization or
through Fc receptors on immune cells (Fig S3B, Video 8). Within the
sites of lung metastasis, we observed a marked increase in c-fms-
EGFP, dextran, and SDS3-HyLite 555 triple-positive macrophages
surrounding lung metastatic foci (Figs 3A and S3C). These results
demonstrate that SDS3 labels myeloid cells that have invaded into
the TME, possibly because of a high concentration of active MMP9
around these cells.
To understand the dynamics of SDS3 within the lung microenvi-
ronment further, we performed ex vivo time-lapse imaging of the
lungs of MMTV-PyMT mice. We observed that SDS3-HyLite 555+ cells
swarm around GFP+ metastatic foci (Figs 3B and S3D, Videos 3 and 4).
Flow cytometric analysis revealed that SDS3-HyLite 555 was taken up
by a number of different myeloid cell types, including macrophages
as well as patrolling and conventional monocytes (Fig 3C).
To confirm that SDS3 accumulates in tumor-bearing organs, we
conjugated SDS3 to a far-red fluorophore (SDS3-HyLite 750), which
visualized the biodistribution using bioluminescent whole-body
imaging as well as ex vivo fluorescent and bioluminescent whole-
mount imaging. In late-stage tumor-bearing MMTV-PyMT mice, the
antibody accumulated in the primary tumor (Fig 3D). Similarly, in WT
mice i.v.-injectedwith VO-PyMT cells, SDS3-HyLite 750 accumulated in
the metastasis-bearing lungs, as well as in the liver, kidneys, and
spleen, organs that clear antibodies (Fig 3D). SDS3-HyLite 750 was
retained in the metastatic lungs 24 h postinjection, when IgG-HyLite
750 had cleared (Fig 3E). These results indicate that SDS3 accumu-
lates within both primary and metastatic tumor foci.
Inhibition of MMP9 activity by SDS3 attenuates migration,
invasion, and colony formation of metastatic cells
Gene expression profiling by quantitative PCR (qPCR) showed that
VO-PyMT cells express higher levels ofMmp9 transcripts and higher
right—representative fluorescent whole lung images of WT control and MMTV-PyMTmice. Right: metastatic burden as quantified by the GFP+ signal in WT control andMMTV-
PyMTmice (n = 13WT and n = 15 PyMT, P = 0.032) 4 wk after i.v. injection of VO-PyMT-GFP-Luc cells. (C) Left: representative fluorescent whole lung images after a 2-wk chase inWT
control and MMTV-PyMT mice. Scale bar is 200 μm. White arrows point to GFP+ metastatic foci. Middle: representative H&E images of lung metastases in WT littermate control
and MMTV-PyMT mice. Right: quantification of the metastatic burden after a 2-wk chase in WT control and MMTV-PyMT mice (n = 11 WT and n = 12 PyMT, P = 0.014). (D)
Schematic of the experimental setup: 6-wk-old MMTV-PyMT mice or WT littermate controls were i.v. injected with 5 × 105 LAP0297-GFP-Luc cells. Mice were monitored weekly
using bioluminescence imaging and euthanized 3 wk after i.v. injection. The lungs were evaluated by whole-mount fluorescence imaging to detect and quantify lung
metastases. (E) Left: bioluminescence imaging of WT control (top) and MMTV-PyMT (bottom) mice after i.v. injection with 5 × 105 LAP0297-GFP-Luc probing cells. Middle:
representative H&E images of lung metastases in WT control and MMTV-PyMT mice after a 3-wk chase. Scale bar is 200 μm. White arrows point to regions of metastatic foci.
Right: quantification of bioluminescence signal in WT control and MMTV-PyMT mice i.v. injected with LAP0297-GFP-Luc cells (n = 4 WT and n = 4 PyMT).
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levels of active MMP9 compared with non-transformed mouse
mammary epithelial cells (Figs 4A and S4A). To determine the ef-
fects of SDS3 directly on metastatic BC cells, we first i.v. injected ten
times more VO-PyMT cells into 6-wk-old WT mice compared with
MMTV-PyMT mice (Fig 4B). This would saturate the system with
probing cells so that these would potentially supply enough MMP9
locally to facilitate their colonization. Mice treated with the SDS3
antibody had significantly reduced metastatic growth and reduced
Figure 2. MMP9 is present in cells within the metastatic
microenvironment.
Early niche formation is accompanied by increased
inflammatory CD11b+Gr1+ myeloid cells that surround islands of
metastatic cells in the lung. (A) Flow cytometric quantification
of neutrophils (Ly6G+CD11b+), T Cells (CD3+CD11b−), CD11b DCs
(CD11b+CD103−), CD103 DCs (CD103+CD11b−), macrophages
(CD11c+Ly6C+Ly6G−), conventional monocytes (Ly6C+CD11c−),
and patrolling monocytes (CD11c+Ly6Clow) gated on live CD45+ in
the lungs of 9-wk-old WT littermates and MMTV-PyMT females 3
wks after i.v. injection of VO-PyMT-GFP-Luc cells (n = 4WT, n = 3
MMTV-PyMT). (B) Left: flow cytometry analysis of CD11b+Gr1+ cells
in GFP+ and GFP− areas of MMTV-PyMT 2 wk after i.v. injection of
VO-PyMT-GFP-Luc cells. Middle and right: confocal
microscopy of 8-wk-old MMTV-PyMT lungs stained with GFP
(green) to mark the injected VO-PyMT-GFP-Luc cells and Gr1
(red). Nuclei are stained with DAPI. Gr1+ (arrows) cells
accumulate around the metastatic GFP+ foci but not in GFP−
areas. (C) Bioinformatics analysis of 90 BC patients with nine
matched pair samples of chest wall, lymph node, lung, liver,
and spleen (Waldron et al, 2012). MMP9 is significantly increased
(P = 0.0014) across various metastatic organs, whereas MMP2 is
decreased across various metastatic organs compared with
primary breast tumors. (D) Confocal microscopy of MMTV-PyMT
lungs stained with GFP (green), MMP9 (red), and Gr1 (blue) shows
colocalization of MMP with Gr1+ cells (denoted by
arrowheads). (E) VO-PyMT-GFP-Luc cells were i.v. injected into 6-
wk-old MMTV-PyMT; Mmp9 WT or MMTV-PyMT; Mmp9 KO. H&E
images of the primary tumor and lung in Mmp9 WT and Mmp9
KO mice after a 3-wk chase. (F) Quantification of the lung
metastatic burden in MMTV-PyMT; Mmp9 WT and MMTV-PyMT;
Mmp9 KO mice after i.v. injection of VO-PyMT-GFP-Luc cells
(n = 4 MMTV-PyMT+; Mmp9 WT, n = 3 MMTV-PyMT+; Mmp9 KO).
Mammary gland scale bar is 300 μmand lung scale bar is 700 μm.
(G) Quantification of in situ zymography in lungs of WT control
and MMTV-PyMT mice at various ages encompassing the
hyperplasia to carcinoma transition (6–7-wk old: n = 6 WT, n = 7
MMTV-PyMT; 8–10-wk old: n = 4 WT, n = 4 MMTV-PyMT). Four
serial sections stained. (H) Schematic of experimental setup:
SDS3 or IgG (isotype control) is preinjected i.p. into 6-wk-old
MMTV-PyMT mice. 1 d later, 1 × 105 VO-PyMT-GFP-Luc cells,
along with SDS3 or IgG, are i.v. injected into the mice.
Subsequently, SDS3 or IgG is i.p. injected every other day for eight
additional injections. (I) Left: whole-mount lung fluorescence
imaging of lung metastases in MMTV-PyMT mice treated with
SDS or IgG. Right: quantification of metastatic burden in MMTV-
PyMT mice treated with SDS or IgG. (n = 8 IgG and n = 9 SDS3;
*P = 0.02). (J) Quantification of primary tumor burden/body
weight in MMTV-PyMT mice treated with SDS or IgG (n = 8 IgG and
n = 9 SDS3, P = not significant). (K) Quantification of in situ
zymography of the lungs in SDS3 and IgG-treated MMTV-PyMT
mice (n = 3 each).
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gelatinolytic activity compared with control mice (Figs 4C and D, and
S4B).
We next determined if blocking MMP9 had direct effects on the
tumor cells in vitro. Although SDS3 treatment had no effect on
VO-PyMT cell viability in vitro (Fig 5A), in a two-dimensional scratch
assay, SDS3 significantly inhibited migration (Figs 5B and S5A).
Although Mmp2 was elevated, this did not compensate functionally
for the inhibition of MMP9. Mmp3, a potent activator of MMP9
Figure 3. SDS3 concentrated within
and around primary tumor and
metastatic foci.
(A) Left: schematic of experimental setup
for imaging MMTV-PyMT; ACTB-ECFP
i.v. injected with VO-PyMT-GFP-Luc cells
and SDS3-HyLite 750. Right: top—primary
tumor confocal microscopy 24 h after
SDS3 injection into MMTV-PyMT; ACTB-
ECFP mice shows SDS3 present within
tumor stroma (n = 8). See Video 1 for
full video of still shots shown;
bottom—metastatic lung confocal
microscopy 24 h after SDS3 injection
into MMTV-PyMT; ACTB-ECFP mice
shows SDS3 accumulating at the
metastatic sites as compared with
lung parenchyma (n = 5). See Video 2 for
full video of still shots shown. (B) An
MMTV-PyMT; ACTB-ECFP mouse was
i.v. injected with VO-PyMT-GFP-Luc cells.
1 wk later, SDS3-HyLite 555 was injected
24 h before imaging followed by near-
infrared (NIR) 10-kD dextran and anti-
Gr1 antibody 5 h before imaging.
Representative images of confocal
microscopy show NIR 10-kD dextran and
anti-Gr1 antibody (white) accumulate
around VO-PyMT metastasis (green)
and SDS3-HyLite 555 (red) (n = 5). See
Videos 3 and 4 for full video of still shots
shown. (C) A representative flow
cytometry analysis of the lungs of
MMTV-PyMT mice 24 h after i.v. injection
of VO-PyMT-GFP-Luc cells and treated
with SDS3 or IgG isotype control. (D) Left:
1 × 105 VO-PyMT-GFP-Luc cells were i.v.
injected into MMTV-PyMT mice along
with SDS3-HyLite 750. MMTV-PyMT mice
IVIS image depicts high intensity of
signal resting within the lungs 24 h
after injection (n = 3). Right: 1 × 106 VO-
PyMT-GFP-Luc cells were i.v. injected into
WT mice along with SDS3-HyLite 750.
Fluorescent IVIS whole-body imaging
shows localization of SDS3-HyLite 750
and bioluminescent IVIS whole-body
imaging shows VO-PyMT-GFP-Luc cells
seeding within the lungs of WT mice
(n = 3). (E) Ex vivo fluorescent and
bioluminescent imaging of various
organs from WT mice i.v. injected with 1 ×
106 VO-PyMT-GFP-Luc shows that the
strongest signal was detected in the
lung, indicating SDS3 accumulation at
themetastatic site with no retention of
IgG isotype control within the lungs (n = 3
IgG-HyLite 750, n = 3 SDS3-HyLite 750).
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(Vempati et al, 2007), was elevated but was not sufficient to rescue the
phenotype. Tenascin C (Tnc), a gene expressed in cancer cells on the
invasive front (Lowy & Oskarsson, 2015), was down-regulated post-
SDS3 with no change in caspase 3, a pro-apoptotic marker. In addition,
there were no noticeable changes in tumor suppression, proliferation,
or epithelial-to-mesenchymal transition (EMT), as reflected by Loxl4,
periostin, and E-cadherin expression levels (Fig 5C). We confirmed that
SDS3 inhibited ECM invasion using a Matrigel-coated trans-well
invasion assay (Figs 5D and S5B). Although VO-PyMT cell viability
remained unaffected (Fig 5A), we observed a down-regulation of
proliferation markers, including c-Myc and Ki67 (Fig 5E).
To validate our in vitro characterization of migration and in-
vasion, we used ex vivo confocal microscopy on the lungs of
MMTV-PyMT mice 24 h after injecting SDS3-HyLite 555 or IgG control.
Time-lapse imaging illustrated reduced migration of VO-PyMT cells
after injection of SDS3 (Fig 5F, Videos 5 and 6). These data further
confirm that SDS3 attenuates the ability of VO-PyMT cells to migrate
and subsequently invade into the lungs.
Finally, we examined whether SDS3 affected the stem-like,
colony formation characteristics of VO-PyMT cells, which are crit-
ical for metastatic colonization. SDS3 treatment significantly re-
duced the number and size of colony-forming spheres when
Figure 4. SDS3 inhibits experimental lung metastases from circulating, MMP9-producing VO-PyMT metastatic cells.
(A) Left: qPCR of Mmp9 levels in VO-PyMT-GFP-Luc cells and the normal mammary cell lines EpH4 and NMuMG. Right: gel zymography of indicated cell lines
demonstrating MMP9 activity. (B) Schematic of experimental setup: 1 × 106 VO-PyMT-GFP-Luc cells along with IgG isotype control or SDS3 was i.v. injected into WT mice.
Subsequently, the antibodies were i.p. injected every other day for eight times before the mice were euthanized. Weekly bioluminescence imaging was performed to
monitor the growth of the i.v.–injected tumor cells. (C) Left: bioluminescent imaging of 9-wk-old WT mice 3 wk after i.v. injection of VO-PyMT-GFP-Luc probing cells.
Middle: representative fluorescent whole lung images of WT mice treated with SDS3 or IgG after a 3-wk chase. Right: quantification of the lung metastatic burden in WT
mice treated with SDS3 or IgG (n = 9 IgG, n = 9 SDS3). (D) Quantification of in situ zymography of lungs in WT mice treated with SDS3 or IgG (n = 3 each).
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Figure 5. SDS3 blocks migration, tissue invasion, and colony formation of MMP9-producing VO-PyMT tumor cells.
(A) MTT assay of VO-PyMT cells treated with 0, 0.125, 0.3125, 0.625, or 1.25 mg/ml of SDS3 or IgG isotype control. The selected concentrations are equivalent to treating
mice with 0, 1, 2.5, 5, and 10 mg/kg of antibody, respectively. (B) Left: representative images of scratch assay. VO-PyMT cells were treated with 0.625 mg/ml of IgG or SDS3.
Area in between the white lines depict the width of area that cells have not migrated back into. Right: quantification of the scratch edge distance (between white lines)
after treatment with IgG or SDS3 at the indicated time points (n = 4 IgG, n = 4 SDS3). (C) qPCR analysis of indicated targets in VO-PyMT cells after scratch and 72 h of IgG or
SDS3 treatment. Triplicate conditions were performed for each target with two biological replicates. (D) Left: trans-well migration assay of VO-PyMT, GFP+ cells in vitro
MMP9 in breast cancer anti-metastatic therapy Owyong et al. https://doi.org/10.26508/lsa.201800226 vol 2 | no 6 | e201800226 8 of 16
compared with IgG control (Figs 5G and S5C). In line with the ex-
pression profile seen with the scratch assay, we found that Mmp2
and Mmp3 were up-regulated, whereas Mmp9 levels were un-
affected (Fig 5H). Taken together, our data demonstrate that MMP9
inhibition with SDS3 attenuated migration, invasion, and colony-
forming ability independent of regulating Mmp9 mRNA levels.
Functional inhibition of MMP9 enhances CD8+ T cell invasion and
activation at sites of metastasis
Our analysis of invasiveness also suggested potential modulation
of the immune landscape after inhibition with SDS3. Specifically, we
observed (Fig 5E) (i) decreased Tgfβ2 and Tgfβ3, which regulate
invasiveness, (ii) a trend towards an anti-tumorigenic cytokine
profile with up-regulation of Ifngr and Cd274 (which encodes
programmed death-ligand 1 [PD-L1]), and (iii) an increase in caspase 8,
which activates a signaling cascade to recruit activated T cells (Fig 5C
and H) (Newton & Strasser, 2003; Plaks et al, 2015). Previous work has
demonstrated that activation of the immune system causes sub-
sequent up-regulation of PD-1/PD-L1 and is thought to be partially
induced by IFNγ (Keir et al, 2008). Based on our findings, we hy-
pothesized that SDS3 treatment may affect the metastatic microen-
vironment by tilting the balance towards Th1 immunity.
We then examined changes in immune function before changes
in metastatic burden, 1 wk after SDS3 treatment. Interestingly, we
observed significant activation of T cells in both the primary tumor
and lungs, characterized by elevated inducible T-cell costimulator
(ICOS+) and CD25+ cells, with no differences in the number of
regulatory T cells (Tregs) (Figs 6A and S6A–D). Although we saw an
activation of immune cells present within the primary tumor,
histological sections of the mammary glands showed no noticeable
difference in tumor stage and progression (Fig S6E). Although both
CD4+ and CD8+ T cells had elevated levels of ICOS (Figs 6B and S7A),
only CD8+ICOS+ T cells exhibited elevated levels of IFNγ, a key
cytokine mediating the cytotoxic activity of CD8+ T cells (Figs 6C and
D and S7B). These activated CD8+ T cells also exhibited significantly
elevated PD-1, which indicate recent T-cell activation (Figs 6E and F
and S7C and D) (Keir et al, 2008). Furthermore, we observed changes
in the myeloid population (Fig S7E and F), including a significant
increase in neutrophils, which is associated with T-cell activation
(Uribe-Querol & Rosales, 2015).
Since MMP9 is an activator of TGFβ, which directly impacts T-cell
responses (Juric et al, 2018; Tauriello et al, 2018), we investigated
whether SDS3 treatment affects the effector T-cell compartment.
Our in vitro analyses (Fig 5) on tumor cells showed an up-regulation
of Cd274, associated with activation of the immune system (Keir
et al, 2008), and down-regulation in Ccl5. Interestingly, qPCR of MMTV-
PyMT lungs 1-wk post-treatment showed reduction in Tgfβ1 and
Alk-5, a subunit of Tgfβ1r, with an elevation in interleukin-12 (IL-12),
a proinflammatory Th1 cytokine, suggesting that SDS3 abrogated
immunosuppression (Fig 6G). These results suggest that MMP9
regulates aspects of the immune response, specifically, elevation of
IFNγ, inducing a shift towards an anti-tumorigenic lung microen-
vironment. Treatment with SDS3 enhanced CD8+ T-cell infiltration
into the metastatic lung, concentrating around metastatic foci (Figs
6H and S7G and H). Overall, these data demonstrate that blocking
MMP9 using SDS3 affected not only multiple intrinsic properties of
tumor cells but also affected recruitment and activation of CD8+ T
cells in the lung microenvironment, which ultimately contributed to
an anti-metastatic immune response (Fig 7).
Discussion
In this study, we demonstrate that a metastatic niche is established
early during tumorigenesis in MMTV-PyMT, an autochthonous,
immune competent mouse model of luminal B BC. This metastatic
niche was driven, at least in part, by MMP9, which was supplied by
CD11b+Gr1+ myeloid cells, among other cells, which establish the
lung metastatic niche (Kowanetz et al, 2010; Casbon et al, 2015;
Wculek & Malanchi, 2015). This metastatic niche facilitates the
colonization and growth of CTCs. Interestingly, once clusters of
tumor cells are formed in the lungs, thesemyeloid cells accumulate
predominantly around the metastatic foci.
We show that SDS3, a unique antibody that targets the active
site of gelatinases, had anti-metastatic activity and primarily
suppressed metastatic growth in the lungs, without significantly
affecting primary tumor burden. Specifically, SDS3 mediated
inhibition of tumor cell–intrinsic properties, such as migration,
invasion, and colony-forming ability, which are required for met-
astatic colonization. In addition, SDS3 led to an enhanced immune
response by increasing recruitment and activation of CD8+ cytotoxic
T cells around metastatic foci. In examining the effect of SDS3 on
the primary tumor, once tumor foci had been established within the
TME, MMP9 no longer played a critical role in tumor growth, ren-
dering SDS3 ineffective (Fig 7). Our results showed that MMP9 is
necessary for the priming of the metastatic niche to enable met-
astatic growth, but further work is required to uncover when
metastatic cells in our model become independent of MMP9
supplied by the stroma in vivo.
Our study suggests that MMP9 inhibition may be an important
strategy in controlling the establishment of the metastatic niche,
predominately early during tumorigenesis before widespread
dissemination of tumor cells into circulation. This supports the
treated with 0.375 mg/ml of SDS3 or IgG for 24 h. Right: quantification of the number of cells migrating through a Matrigel-lined insert after SDS3 or IgG treatment/
incubation. (n = 6 IgG, n = 6 SDS3). (E) qPCR analysis on IgG or SDS3-treated trans-well invasion assay VO-PyMT, GFP+ cells 24 h posttreatment. Significant down-regulation of
Mmp9 captured using a 3D invasion assay, whereas no change in Mmp2 provides evidence of SDS3 specifically targeting MMP9. Triplicate conditions performed for each
gene with two biological replicates. (F) Ex vivo confocal microscopy of MMTV-PyMT mice showing migrating VO-PyMT, GFP+ cells (arrows) in mice 24 h after injection with
IgG-HyLite555 as compared with none inmice injected with SDS3-HyLite 555. See Videos 5 and 6 for full video of still shots shown. (G) Left: representative images of a colony
formation assay using VO-PyMT cells (4,000 cells/well) treated with 0.625 mg/ml of IgG or SDS3. Arrows depict the categorization of small (red), medium (green), and large
(blue) spheres. Right: quantification of sphere size in each well (n = 2 biological replicates with seven replicates per condition and five images per well quantified). (H)
qPCR analysis on IgG- and SDS3-treated sphere assay of VO-PyMT cells 5 d posttreatment. Elevation ofMmp2 but no noticeable change inMmp9 transcript levels supports
the specificity of SDS3. Triplicate conditions performed with two biological replicates.
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Figure 6. SDS3 promotes CD8+ T cell activation and T cell infiltration.
(A) Flow cytometry analysis of early immune changes within the lungs of MMTV-PyMT mice i.v. injected with 1 × 105 VO-PyMT-GFP-Luc cells at 7 wk of age treated with
SDS3 or IgG isotype control. Counting beads used to normalize frequencies with absolute cell counts standardized to isotype control expressed as a relative difference
from the average isotype control absolute cell count. Significant activation of T cells seen through marked elevation of ICOS and CD25 (n = 3 IgG, n = 4 SDS3). (B) Flow
cytometry analysis of ICOS-activated T cells reveals both CD4 and CD8 T cell subsets significantly up-regulated after SDS3 treatment. (C) Flow cytometry analysis of IFNγ
within CD4- and CD8-activated T cells (ICOS+) demonstrates prominent Th1 cytokine skewing of CD8 T cells after SDS3 treatment. (D) Representative scatterplot of ICOS+
MMP9 in breast cancer anti-metastatic therapy Owyong et al. https://doi.org/10.26508/lsa.201800226 vol 2 | no 6 | e201800226 10 of 16
notion that tumor cell dissemination occurs early during BC pro-
gression (Lambert et al, 2017). Therefore, identifying these early
niche changes in human patients may yield additional therapeutic
strategies to block metastatic cell colonization and proliferation at
distant sites. One of the major drawbacks of studies thus far that
have investigated early metastatic niche formation is utilization of
late-stage and extremely aggressive tumor cell line transplants
(e.g., B16 melanoma, Lewis lung carcinoma, and 4T1 breast carci-
noma) into mice. These models do not capture the initial changes
that occur early during tumor development, and thus, it remains
unclear whether the factors identified thus far play roles in early
tumorigenesis. From a clinical perspective, this distinction is critical
because early tumors (or recurring hyperplasia) may secrete factors
that predispose the patient to metastatic colonization years later.
This suggests that some patients may benefit from the therapy to
control or delay the onset of occult metastases, even when there is
no radiographic evidence to suggest disseminated or metastatic
disease. With some clinical trials now usingmetastasis-free survival
as a clinically meaningful endpoint (Smith et al, 2018), the ability to
inhibit and delay metastasis is important.
In early stages of metastatic colonization, we postulate that
there is a minimum threshold of active MMP9 within the TME re-
quired for the priming of the premetastatic niche to be more
susceptible for colonization. We also showed that the primary
tumor could also provide MMP9 that could be responsible for in-
vasion and metastasis. Within the MMTV-PyMT model, neutrophils
have been recently implicated as principal players in cancer ini-
tiation and progression (Coffelt et al, 2016). More specifically, Alox5
expression can promote downstream metastatic effects through
induction of MMP9 (Kummer et al, 2012). We observed MMP9-
mediated priming of the metastatic niche within the MMTV-PyMT
mouse model and showed that MMP9 (and not MMP2) dominates
metastasis in human BC and in the MMTV-PyMT model with genetic
ablation of MMP9. Interestingly, exosomal MMPs have been thought
to also assist in the proteolytic remodeling process of the ECM
through activation of MMP2 (Shay et al, 2015).
In addition, T cells can be inactivated by inflammatory cells in the
microenvironment (Grivennikov et al, 2010). Identifying and tar-
geting suppressive signals could be impactful in remodeling the
immune landscape to tilt the balance towards an anti-tumorigenic
CD8 T-cell expression of IFNγ. Red box represents IgG-treated activated CD8 T cells expressing IFNγ. Green box represents SDS3-treated activated CD8 T cells expressing
IFNγ. (E) Flow cytometry analysis of PD-1 within CD8+-activated T cells (ICOS+) shows significant up-regulation of an exhausted T-cell response due to overactivation of the
immune system. (F) Representative scatterplot of ICOS+ CD8 T-cell expression of PD-1. Red box represents IgG-treated activated CD8 T cells expressing PD-1. Green box
represents SDS3-treated activated CD8 T cells expressing PD-1. (G) qPCR analysis of MMTV-PyMT lungs i.v. injected with 1 × 105 VO-PyMT-GFP-Luc cells 1 wk after IgG or
SDS3 treatment shows decreased Th2/M2-like markers (Il-4r and Egr2) and increased Il-12 (duplicate conditions with n = 4 IgG and n = 4 SDS3). (H) Left: representative
immunofluorescence images of 9-wk-old MMTV-PyMT lungs i.v. injected with 1 × 105 VO-PyMT-GFP-Luc cells 3 wk after IgG or SDS3 treatment. CD8+ T cells localize around
GFP+metastatic sites (arrows) after IgG and SDS3 treatment, whereas lower presence of CD8+ T cells seen around GFP− sites. Middle: quantification of CD8+ T cells in GFP+
and GFP− regions 3 wk after IgG and SDS3 treatment (not shown: GFP− foci). Right: CD8+ T cell infiltration around periphery and within GFP+ metastatic foci in MMTV-PyMT
mice at 9-wk of age after a 3-wk chase post i.v. injection of 1 × 105 VO-PyMT GFP+ cells (n = 5 IgG, n = 5 SDS3; three serial sections used for quantification).
Figure 7. Summary of SDS3’s effect within the TME
and changes in immune architecture after
inhibition of active MMP9.
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TME, ultimately prolonging overall survival. Interestingly, TGFβ is
associated with resistance to anti–PD-L1 by promoting T-cell ex-
clusion in bladder cancer (Lau et al, 2017) and colorectal cancer
(Tauriello et al, 2018). Targeting TGFβ alone showed efficacy against
a metastatic disease but had no effect on the primary tumor (Lau
et al, 2017; Tauriello et al, 2018). Because MMP9 is a known activator
of TGFβ (Tauriello et al, 2018), therapy targeting active MMP9 in
combination with checkpoint inhibitors is warranted as a future
direction. With recent developments in bifunctional approaches to
perturb the immune system, specifically using TGFβ/PD-L1 (David
et al, 2017; Lan et al, 2018; Ravi et al, 2018), modulating the ECM in
cancers currently resistant to checkpoint inhibitor monotherapy
may increase the efficacy.
Understanding mechanisms to modulate the microenviron-
ment for the optimization of checkpoint blockade therapy are
currently underway (Mariathasan et al, 2018; Owyong et al, 2018).
For example, the effects of an anti-MMP9 monoclonal antibody
(GS-5745) are being examined in combination with nivolumab
(anti-PD-1) and other anticancer drugs for recurrent gastric and
gastroesophageal adenocarcinoma (clinicaltrials.gov). This sug-
gests the possibility to modulate the microenvironment during
early metastatic growth to get better responses in BC patients who
generally arrive at the clinic with an established primary tumor
and have developed early metastases to form micrometastatic
foci. In their totality, our data demonstrate that regulation of the
ECM by targeting MMP9 alters the hallmark metastatic processes
of migration, invasion, and colony formation and remodels the
immune landscape, redefining MMP9 as an immunemodulator for
BC therapy. Taken together, targeting MMP9 may be an effective
combination therapy and suggests that perturbing the MMP9–




All animal experiments were performed at University of California,
San Francisco (UCSF) and reviewed and approved by UCSF Institu-
tional Animal Care and Use Program. Mice were housed under
pathogen-free conditions in the UCSF barrier facility. FVB/n mice,
originally from Charles River, were bred in-house or purchased
through Charles River. For premetastatic niche setup, 6-wk-old
MMTV-PyMT female mice were i.v. injected with 1 × 105 VO-PyMT
probing cells in PBS. For experimental metastasis experiments, 6-wk-
old WT female mice were i.v. injected with 1 × 106 VO-PyMT probing
cells in PBS. For genetic examination of total MMP9, MMTV-PyMT;
MMP9 mice were crossed. Therapeutic antibody was i.p. injected
using 5 μg/g (per injection) using SDS3, HyLite 750 conjugated SDS3
(IVIS imaging), HyLite 555 conjugated SDS3 (confocal imaging), or a
nonspecific isotype (IgG1, MOPC-21). Dr. Irit Sagi’s group prepared
SDS3 as described previously (Sela-Passwell et al, 2011).
Tumor measurements were made using a caliper once per week.
Bioluminescent imaging was performed using an IVIS Spectrum and
image radiance normalized using Living Image (Caliper LifeScience).
For whole-mount fluorescent imaging, mouse lung lobes were
squeezed between two glass slides, removing the volumetric di-
mension to achieve area in square millimeter using ImageJ.
Cell culture
The PyMT cell line VO-PyMT (Halpern et al, 2006) was a gift from Conor
Lynch (Moffitt Cancer Center). The LAP0297 cell line, generated from a
spontaneous lung carcinoma in FVB/nmice (Huang et al, 2008), was a
gift from Peigen Huang (Massachusetts General Hospital). The cells
were transduced with pMSCV-luciferase to generate a luciferase-
expressing cell line and with pMIG to generate a GFP-expressing cell
line. Cell sorting was performed on a FACS Aria II (Becton Dickinson),
and the cells were grown in DMEM, high glucose (11965; Gibco)
supplemented with 10% FBS and 1% penicillin–streptomycin.
Retroviral production
Viral production was carried out using calcium phosphate–
mediated transfection of HEK293T/GP2 cells. Virus was concen-
trated by ultracentrifugation and added to cells with polybrene.
Stably transduced cells were selected in puromycin for at least 5 d
or selected by FACS.
qPCR
Total RNA was isolated from cells using the RNeasy Mini Kit
(QIAGEN). cDNA was synthesized using the Superscript III RT First
Strand Kit (Invitrogen). qPCR was performed using FastStart Uni-
versal SYBR Greenmaster mix (Roche) in an Eppendorf Mastercycler
Realplex machine. Ct values were normalized to GAPDH and actin,
and relative expression was calculated using the 2−DDCt method.
Primer sequences for qPCR were found using the Harvard Primer
Bank and are detailed in Table S1.
Immunostaining and histology
Tissues were fixed in 4% PFA overnight, paraffin processed or
embedded into OCT for frozen sections, and sectioned. Hematoxylin
and eosin staining was performed for routine histology. Antigen
retrieval was performed using citrate or proteinase K for immuno-
histochemistry. The Tyramide Signal Amplification Kit (#NEL700A001KT;
Perkin Elmer) was used according to the manufacturer instructions.
Primary antibodies were incubated overnight and secondary anti-
bodies were incubated for 1 h. The following antibodies were used:
phosphohistone H3 (#9701, 1:100; Cell Signaling), CD8a (16-0081, 1:500;
eBioscience), GFP (ab290, 1:500; Abcam), biotinylated antirat (#112-067-
003, 1:300; Jackson), biotinylated antirabbit (#E0431, 1:300; Dako), and
biotinylated antigoat (#305-067-003, 1:300; Jackson). Fluorescent
antibodies 488-antirabbit, 568-antirat, and 647-antirat were from
Molecular Probes (#A11008, #A11077 and A-21247, 1:600; Invitrogen),
with fluorescent microscopy performed on a Keyence BZ-X700. Image
analysis was performed using ImageJ.
In situ zymography and immunofluorescence
Gelatinolytic activity was assessed by in situ zymography of zinc-
buffer fixative (36.7 mM ZnCl2, 27.3 mM ZnAc2 × 2H2O, and 0.63 mM
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CaAc2 in 0.1 mol/l Tris, pH 7.4), paraffin-embedded sections of lungs
and mammary gland from 6- to 10-wk-old MMTV-PyMT mice. Sec-
tions were heated at 59°C for 3 h, deparaffinized in xylene, and
rehydrated in graded alcohol baths. Substrate was prepared by
dissolving 1 mg DQ gelatin (Molecular Probes; Thermo Fisher Sci-
entific) in 1.0 ml Milli-Q water and further diluted 1:50 in a reaction
buffer containing 50 mM Tris–HCl, 150 mM NaCl, and 5 mM CaCl2 (pH
7.6). Sections were covered with the substrate solution and par-
afilm, and then incubated for 2 h in a dark, humid chamber at 37°C.
The parafilm was removed, then the sections were rinsed with Milli-
Q water, and washed in PBS (2 × 5 min). The sections were then
incubated with DAPI (diluted 1:10,000; Molecular Probes/Thermo
Fisher Scientific) for 5 min, washed in PBS baths (2 × 5 min), and
mounted with Fluorescent Mounting Medium (Dako). Contribution
of MMPs to the observed gelatinolytic activity and the level of auto
fluorescence in the tissues was assessed by incubating parallel
sections with 20 mM EDTA added to the substrate solution or
without DQ gelatin added to the reaction buffer, respectively. In
some sections, the SDS3 antibody was added to the substrate
solution (diluted 1:50) to assess contribution of MMP9 to the
gelatinolytic activity. Fluorescent microscopy performed on Key-
ence BZ-X700 with 10× magnification at randomly selected fields
and quantified using ImageJ by measuring the inner and outer ring
integrated density of the GFP area standardized to WT of each age
group.
7-wk time point WT and MMTV-PyMT sections were immuno-
fluorescently stained for MMP2, MMP9, CD3, F4/80, and Gr1 after in
situ zymography procedures (before DAPI staining) to determine if
gelatinolytic activity co-localized with these enzymes. After sub-
strate incubation and rinsing, the sections were incubated for 1 h at
room temperature with a blocking solution containing 5% goat
serum, 0.1% Triton X-100, and 0.05% Tween 20 in PBS to block
nonspecific binding of the antibody. Sections were then incubated
for 1 h (room temperature in a dark, humid chamber) with primary
antibody (MMP2 [ab37150; Abcam, diluted 1:50 in blocking solution]
or MMP9 [ab388898; Abcam, diluted 1:500 in blocking solution]),
rinsed in PBS with 0.05% Tween20 (PBST) 5 min × 3, and incubated
for 1 h (room temp. in a dark, humid chamber) with secondary
antibody (Alexa Fluor 633 [AF633], goat antirabbit IgG [Molecular
Probes, diluted 1:400 in blocking solution]). These sections were
also incubated with primary antibody (F4/80 [Molecular Probes
MF4800 diluted 1:20 in blocking buffer], CD3 [MAC2690T; Bio-Rad
diluted 1:40 in blocking buffer], and Gr1 [MA1-70099; Thermo Fisher
Scientific diluted 1:20 in blocking buffer]) at 4°C overnight. They
were rinsed in PBST for 3 × 5 min and subsequently incubated with
secondary antibody (AF 633, goat antirat IgG [A21094; Invitrogen,
diluted 1:200 in blocking buffer], DyLight649, goat anti-Armenian
hamster IgG [Jackson Immuno Research code 127-495-160, diluted
1:200 in blocking buffer]) for 1 h at room temperature followed with
rinsing in PBST 3 × 5 min. The sections were then incubated with
DAPI (Molecular Probes/Thermo Fisher Scientific) (diluted 1:10,000)
for 5 min, washed in PBS baths (2 × 5 min), and mounted with
Fluorescent Mounting Medium (Dako). Fluorescent microscopy was
performed on Keyence BZ-X700. For CD8a quantification, a circle of
defined radius from the perimeter of the GFP+ region was defined




1 × 104 VO-PyMT cells were suspended within complete Matrigel
(CB40234; Corning) and seeded into a round bottom 96-well
plate. DMEM, high glucose (11965; Gibco) with 10% FBS, and 1%
penicillin–streptomycin were added to each well and changed
daily. 0.375 mg/ml of SDS3 and IgG control used per well. Images
were taken using inverted microscope and Leica software at day
0, 4, 5, and 6. Spheres were graded based on size and catego-
rized into small, medium, large, and branching percentages per
well.
Migration assay
VO-PyMT, GFP+ cells were suspended at 1 × 104 cells per 200 μl of
DMEM, high glucose (11965; Gibco) with 1% penicillin–streptomycin
and 0.5% puromycin. 700 μl of DMEM with 2% FBS, 1% penicillin–
streptomycin, and 0.5% puromycin along with 0.375 mg/ml of IgG
control or SDS3 was added into each well of a 24-well flat bottom
plate. FluoroBlok inserts (351152; Corning) were lined with 25 μl of 1:2
diluted growth factor reduced Matrigel (354230; Corning) and in-
cubated for 45 mins at 37°C. VO-PyMT, GFP+ cells were seeded into
FluoroBlok insert and imaged 24 h postseeding. Images were taken
with an inverted fluorescent microscope for GFP+ signal using Leica
software. Each well was split into four quadrants and a random
image was taken within each quadrant at 10× magnification. The
number of migrated, GFP+ cells were counted and compared
against the total number of cells seeded.
Scratch assay
VO-PyMT cells plated onto six-well plates at 5 × 105 cells/2.5 ml and
allowed for form a confluent monolayer for 48 h before T(0). 0.625
mg/ml of IgG or SDS3 was added into each well at T(0) with DMEM,
high glucose, 10% FBS, and 1% penicillin–streptomycin. Images were
taken on a Keyence microscope every 24 h. The distance between
the white lines represents the area that VO-PyMT cells have not
migrated to. Quantification conducted by measuring the distance
between the white lines.
Flow cytometry
To process lungs for FACS, we used 50 μl Liberase (26 units/ml,
5401127001; Sigma-Aldrich) and 50 μl DNase (10 mg/ml, D4263;
Sigma-Aldrich) per animal suspended in 5ml DMEM, high glucose. The
samples were digested using gentleMACS C tubes (130-093-237; MACS),
then incubated after initial homogenization on an oribital shaker for
30min at 37°C, 150 rpm (~0.2g). Lung samples were lysed with RBC lysis
buffer and then filtered through a 70-μm cell strainer before staining.
Fluorescent antibodies used for FACS are listed in Table S2.
For cytokine stimulation, single cell suspension was stimulated
with PMA+ionomycin without Brefeldin A (423301; BioLegend) for 4 h
according to the manufacturer’s instructions and BD GolgiPlug
added 1 h after initial stimulation. After extracellular staining, the
cells were fixed and permeabilized using the BD Cytofix/Cytoperm
Plus (555028; BD Biosciences) and then stained for intracellular
markers.
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Confocal microscopy
Details of the microscope design as well as a detailed protocol for
ex vivo lung imaging were previously described (van den Bijgaart
et al, 2016). To image lung capillaries, mice were i.v. injected with 100
μl sterile PBS containing 4 mg/ml 10 kD AF647-conjugated dextran
or 4 mg/ml 70 kD rhodamine-conjugated dextran (Invitrogen). In
addition, to image Gr1+ neutrophils and monocytes, mice were i.v.
injected with 100 μl sterile PBS containing 1 mg/ml AF647-
conjugated Gr-1 antibody 5 h before excision of the lungs. At the
time of lungs’ excision, the mice were euthanized by i.p. injection of
1 ml of 2.5% Avertin. Subsequently, the lungs were inflated with 400
μl of 37°C 2% lowmelting temperature agarose followed by excision
of the lungs. The lungs were immersed in RPMI-1640 and the lobes
were gently separated and then transferred to an imaging plate.
Bioinformatics analysis of illumina microarray
Public microarray datasets were downloaded from the National
Center for Biotechnology Information, Gene Expression Omnibus.
TheMMP family mRNA expression levels were analyzed across three
normal samples and 106 metastasis samples as well as six positive
and five negative controls in GSE32490 dataset. Probe intensities
were analyzed and normalized using the Lumi package in the R
statistical environment as previously described (Du et al, 2008).
Statistical analysis
Statistical analysis was performed using Prism 7 software (GraphPad
Software, Inc.). All data are presented as mean ± SEM, unless oth-
erwise stated. When two groups were compared, the two-tailed t test
was used, unless otherwise stated. When three or more groups were
compared, the one-way ANOVA test was used, followed by Tukey’s
test to determine significance between groups. We considered P < 0.05
as significant.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201800226.
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